Ionis Pharmaceuticals, Inc.

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

– Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – – 49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease

- Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - - Robust reductions in tau pathology were observed across all studied doses, with results generally

Ionis to host 2026 virtual Annual Meeting of Stockholders

CARLSBAD, Calif. --(BUSINESS WIRE)--May 4, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026.

Ionis to present at upcoming investor conferences

CARLSBAD, Calif. --(BUSINESS WIRE)--May 1, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026 2026 RBC Capital

Ionis reports first quarter 2026 financial results and highlights progress on key programs

- TRYNGOLZA ® (olezarsen) showed increasing demand in FCS driven by strong launch execution – - Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track – – Increasing annual TRYNGOLZA peak net sales guidance to > $3B for sHTG – - Zilganersen NDA for Alexander

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

– Regulatory submission supported by Phase 3 B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B - – Breakthrough Therapy designation added to Fast Track Designation, recognizing potential for substantial improvement over

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

– New data highlight potential treatment benefit across multiple AxD symptom domains, reinforcing zilganersen’s positive impact on people living with this rare, often fatal neurological disease – – PDUFA date set for September 22, 2026 – CARLSBAD, Calif. --(BUSINESS WIRE)--Apr.

Ionis to hold first quarter 2026 financial results webcast

Webcast scheduled for Wednesday, April 29 at 8:30 a.m. Eastern Time CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 15, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026

Ionis statement about the Wholesale Acquisition Cost of TRYNGOLZA® (olezarsen)

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

– PDUFA date set for September 22, 2026 – CARLSBAD, Calif. --(BUSINESS WIRE)--Mar. 23, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an

Ionis announces changes to Board of Directors

– Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board – CARLSBAD, Calif. --(BUSINESS WIRE)--Mar. 9, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced upcoming transitions on its Board of Directors. B.

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

CARLSBAD, Calif. --(BUSINESS WIRE)--Feb. 27, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

– PDUFA date set for June 30, 2026 – CARLSBAD, Calif. --(BUSINESS WIRE)--Feb. 26, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

- TRYNGOLZA ® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track, sNDA submitted - - Exceeded 2025 financial guidance, 2026 guidance reflects commitment to independently deliver a steady cadence of innovative medicines to

Ionis to present at upcoming investor conferences

CARLSBAD, Calif. --(BUSINESS WIRE)--Feb. 19, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36 th Annual Healthcare Life Sciences Virtual Conference on Thursday, February 26,